Recent patents on therapeutic applications of the transcription factor decoy approach

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 11, 2011, Pages 1755-1771

  Gambari, Roberto ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Apoptosis; Cancer; Inflammation; Nuclear factor kB; Osteoclasts; Peptide nucleic acids; PNA DNA chimeras; Transcription factor decoy; Transcription factors

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; APTAMER; CISPLATIN; HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 8; MICRORNA; OLIGODEOXYRIBONUCLEOTIDE; OLIGONUCLEOTIDE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 6; TRANSCRIPTION FACTOR NFAT;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLITIS; DRUG STABILITY; GENE CONTROL; GENE INACTIVATION; HUMAN; INNATE IMMUNITY; OLIGONUCLEOTIDE THERAPY; PATENT; PROTEIN BINDING; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION;

ANIMALS; BINDING SITES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GENE EXPRESSION REGULATION; HUMANS; OLIGONUCLEOTIDES; PATENTS AS TOPIC; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 80054962273     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2011.629605     Document Type: Article

References (139)

1. Martiniello-Wilks R, Tsatralis T, Russell P, et al. Transcription- targeted gene therapy for androgen-independent prostate cancer. Cancer Gene Ther 2002;9(5):443-52 (Pubitemid 34438586)
2. Licht JD. Targeting aberrant transcriptional repression in leukemia: a therapeutic reality? J Clin Invest 2001;108(9):1277-8 (Pubitemid 33107753)
3. Chaires JB. Drug-DNA interactions. Curr Opin Struct Biol 1998;8:314-20 (Pubitemid 28321358)
4. Boer DR, Canals A, Coll M. DNA-binding drugs caught in action: the latest 3D pictures of drug-DNA complexes. Dalton Trans 2009;3:399-414
5. Gambari R, Feriotto G, Rutigliano C, et al. Biospecific interaction analysis (BIA) of low-molecular weight DNA-binding drugs. J Pharmacol Exp Ther 2000;294(1):370-7 . One of few examples of determining DNA selectivity of DNA binding drugs using Surface Plasmon Resonance. (Pubitemid 30434710)
6. Sleiman SF, Langley BC, Basso M, et al. Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration. J Neurosci 2011;31(18):6858-70
7. Ciucci A, Feriotto G, Mischiati C, et al. Distamycin analogues with improved sequence-specific DNA binding activities. Biochem Pharmacol 1994;48(8):1583-91 (Pubitemid 24336784)
8. Speight RE, Hart DJ, Blackburn JM. Distamycin A affects the stability of NF-kappaB p50-DNA complexes in a sequence-dependent manner. J Mol Recognit 2002;15(1):19-26 (Pubitemid 34220199)
9. Carbone GM, Napoli S, Valentini A, et al. Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. Nucleic Acids Res 2004;32(14):4358-67 (Pubitemid 39232308)
10. Hildner KM, Schirmacher P, Atreya I, et al. Targeting of the transcription factor STAT4 by antisense phosphorothioate oligonucleotides suppresses collagen-induced arthritis. J Immunol 2007;178(6):3427-36 (Pubitemid 46417607)
11. Na KY, Woo SK, Lee SD, Kwon HM. Silencing of TonEBP/NFAT5 transcriptional activator by RNA interference. J Am Soc Nephrol 2003;14(2):283-8 (Pubitemid 36150850)
12. Sankaran VG, Menne TF, Scepanovic D, et al. MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. Proc Natl Acad Sci USA 2011;108(4):1519-24 .. One of the examples linking microRNA expression and activity of transcription factors.
13. Bontron S, Ucla C, Mach B, Steimle V. Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by a functional selection strategy. Mol Cell Biol 1997;17(8):4249-58 (Pubitemid 27318101)
14. Buitenhuis M, Baltus B, Lammers JW, et al. Signal transducer and activator of transcription 5a (STAT5a) is required for eosinophil differentiation of human cord blood-derived CD34+ cells. Blood 2003;101(1):134-42 (Pubitemid 36025899)
15. Fry DW, Kraker AJ, McMichael A, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994;265(5175):1093-5 (Pubitemid 24293076)
16. Birkenkamp KU, Tuyt LM, Lummen C, et al. The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway. Br J Pharmacol 2000;131(1):99-107
17. Yang X, Fennewald S, Luxon BA, et al. Aptamers containing thymidine 3?-O-phosphorodithioates: synthesis and binding to nuclear factor-kappaB. Bioorg Med Chem Lett 1999;9(23):3357-62
18. Cassiday LA, Maher LJ III. In vivo recognition of an RNA aptamer by its transcription factor target. Biochemistry 2001;40(8):2433-8 (Pubitemid 32171716)
19. King DJ, Bassett SE, Li X, et al. Combinatorial selection and binding of phosphorothioate aptamers targeting human NF-kappa B RelA(p65) and p50. Biochemistry 2002;41(30):9696-706 (Pubitemid 34810045)
20. Dzau VJ. Transcriptional factor decoy. Circ Res 2002;90:1234-6
21. Mann MJ, Dzau VJ. Therapeutic application of transcriptional factor decoy oligonucleotides. J Clin Invest 2000;106:1071-5 .. One of most important review articles on the transcription factor decoy approach.
22. Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element "decoy" against nuclear factor-kB binding site prevents myocardial infarction. Nat Med 1997;3:894-9 (Pubitemid 27353450)
23. Tomita T, Takano H, Tomita N, et al. Transcription factor decoy for NF-kB inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology 2000;39:749-57 (Pubitemid 30488507)
24. Borgatti M, Lampronti I, Romanelli A, et al. Transcription factor decoy molecules based on a peptide nucleic acid (PNA)-DNA chimera mimicking Sp1 binding sites. J Biol Chem 2003;278:7500-9 (Pubitemid 36800757)
25. Karin M, Lin A. NF-kB at the crossroads of life and death. Nat Immunol 2002;3:221-7
26. Yamamoto Y, Gaynor RB. Role of the NF-kB pathway in the pathogenesis of human disease states. Curr Mol Med 2001;1:287-96 (Pubitemid 33773312)
27. Yang X, Karsenty G. Transcription factors in bone: developmental and pathological aspects. Trends Mol Med 2002;8:340-5 (Pubitemid 34733388)
28. Nebert DW. Transcription factors and cancer: an overview. Toxicology 2002;181-182:131-41 (Pubitemid 36015686)
29. Redell MS, Tweardy DJ. Targeting transcription factors for cancer therapy. Curr Pharm Des 2005;11:2873-87 (Pubitemid 41051872)
30. Borgatti M, Bezzerri V, Mancini I, et al. Induction of IL-6 gene expression in a CF bronchial epithelial cell line by Pseudomonas aeruginosa is dependent on transcription factors belonging to the Sp1 superfamily. Biochem Biophys Res Commun 2007;357:977-83 (Pubitemid 46693668)
31. Bezzerri V, Borgatti M, Nicolis E, et al. Transcription Factor Oligodeoxynucleotides to NF-{kappa}B Inhibit Transcription of IL-8 in Bronchial Cells. Am J Respir Cell Mol Biol 2008;39:86-96 (Pubitemid 351883962)
32. Piva R, Penolazzi L, Lambertini E, et al. Induction of apoptosis of human primary
33. Martiniello-Wilks R, Tsatralis T, Russell P, et al. Transcription- targeted gene therapy for androgen-independent prostate cancer. Cancer Gene Ther 2002;9(5):443-52 (Pubitemid 34438586)
34. Licht JD. Targeting aberrant transcriptional repression in leukemia: a therapeutic reality? J Clin Invest 2001;108(9):1277-8 (Pubitemid 33107753)
35. Chaires JB. Drug-DNA interactions. Curr Opin Struct Biol 1998;8:314-20 (Pubitemid 28321358)
36. Boer DR, Canals A, Coll M. DNA-binding drugs caught in action: the latest 3D pictures of drug-DNA complexes. Dalton Trans 2009;3:399-414
37. Gambari R, Feriotto G, Rutigliano C, et al. Biospecific interaction analysis (BIA) of low-molecular weight DNA-binding drugs. J Pharmacol Exp Ther 2000;294(1):370-7 (Pubitemid 30434710)
38. Sleiman SF, Langley BC, Basso M, et al. Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration. J Neurosci 2011;31(18):6858-70
39. Ciucci A, Feriotto G, Mischiati C, et al. Distamycin analogues with improved sequence-specific DNA binding activities. Biochem Pharmacol 1994;48(8):1583-91 (Pubitemid 24336784)
40. Speight RE, Hart DJ, Blackburn JM. Distamycin A affects the stability of NF-kappaB p50-DNA complexes in a sequence-dependent manner. J Mol Recognit 2002;15(1):19-26 (Pubitemid 34220199)
41. Carbone GM, Napoli S, Valentini A, et al. Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. Nucleic Acids Res 2004;32(14):4358-67 (Pubitemid 39232308)
42. Hildner KM, Schirmacher P, Atreya I, et al. Targeting of the transcription factor STAT4 by antisense phosphorothioate oligonucleotides suppresses collagen-induced arthritis. J Immunol 2007;178(6):3427-36 (Pubitemid 46417607)
43. Na KY, Woo SK, Lee SD, Kwon HM. Silencing of TonEBP/NFAT5 transcriptional activator by RNA interference. J Am Soc Nephrol 2003;14(2):283-8 (Pubitemid 36150850)
44. Sankaran VG, Menne TF, Scepanovic D, et al. MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. Proc Natl Acad Sci USA 2011;108(4):1519-24
45. Bontron S, Ucla C, Mach B, Steimle V. Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by a functional selection strategy. Mol Cell Biol 1997;17(8):4249-58 (Pubitemid 27318101)
46. Buitenhuis M, Baltus B, Lammers JW, et al. Signal transducer and activator of transcription 5a (STAT5a) is required for eosinophil differentiation of human cord blood-derived CD34+ cells. Blood 2003;101(1):134-42 (Pubitemid 36025899)
47. Fry DW, Kraker AJ, McMichael A, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994;265(5175):1093-5 (Pubitemid 24293076)
48. Birkenkamp KU, Tuyt LM, Lummen C, et al. The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway. Br J Pharmacol 2000;131(1):99-107
49. Yang X, Fennewald S, Luxon BA, et al. Aptamers containing thymidine 3?-O-phosphorodithioates: synthesis and binding to nuclear factor-kappaB. Bioorg Med Chem Lett 1999;9(23):3357-62
50. Cassiday LA, Maher LJ III. In vivo recognition of an RNA aptamer by its transcription factor target. Biochemistry 2001;40(8):2433-8 (Pubitemid 32171716)
51. King DJ, Bassett SE, Li X, et al. Combinatorial selection and binding of phosphorothioate aptamers targeting human NF-kappa B RelA(p65) and p50. Biochemistry 2002;41(30):9696-706 (Pubitemid 34810045)
52. Dzau VJ. Transcriptional factor decoy. Circ Res 2002;90:1234-6
53. Mann MJ, Dzau VJ. Therapeutic application of transcriptional factor decoy oligonucleotides. J Clin Invest 2000;106:1071-5
54. Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element "decoy" against nuclear factor-kB binding site prevents myocardial infarction. Nat Med 1997;3:894-9 (Pubitemid 27353450)
55. Tomita T, Takano H, Tomita N, et al. Transcription factor decoy for NF-kB inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology 2000;39:749-57 (Pubitemid 30488507)
56. Borgatti M, Lampronti I, Romanelli A, et al. Transcription factor decoy molecules based on a peptide nucleic acid (PNA)-DNA chimera mimicking Sp1 binding sites. J Biol Chem 2003;278:7500-9 (Pubitemid 36800757)
57. Karin M, Lin A. NF-kB at the crossroads of life and death. Nat Immunol 2002;3:221-7
58. Yamamoto Y, Gaynor RB. Role of the NF-kB pathway in the pathogenesis of human disease states. Curr Mol Med 2001;1:287-96 (Pubitemid 33773312)
59. Yang X, Karsenty G. Transcription factors in bone: developmental and pathological aspects. Trends Mol Med 2002;8:340-5 (Pubitemid 34733388)
60. Nebert DW. Transcription factors and cancer: an overview. Toxicology 2002;181-182:131-41 (Pubitemid 36015686)
61. Redell MS, Tweardy DJ. Targeting transcription factors for cancer therapy. Curr Pharm Des 2005;11:2873-87 (Pubitemid 41051872)
62. Borgatti M, Bezzerri V, Mancini I, et al. Induction of IL-6 gene expression in a CF bronchial epithelial cell line by Pseudomonas aeruginosa is dependent on transcription factors belonging to the Sp1 superfamily. Biochem Biophys Res Commun 2007;357:977-83 (Pubitemid 46693668)
63. Bezzerri V, Borgatti M, Nicolis E, et al. Transcription Factor Oligodeoxynucleotides to NF-{kappa}B Inhibit Transcription of IL-8 in Bronchial Cells. Am J Respir Cell Mol Biol 2008;39:86-96 (Pubitemid 351883962)
64. Piva R, Penolazzi L, Lambertini E, et al. Induction of apoptosis of human primary osteoclasts treated with a transcription factor decoy mimicking a promoter region of estrogen receptor alpha. Apoptosis 2005;66:1079-94 (Pubitemid 41285584)
65. Morishita R, Tomita N, Kaneda Y, Ogihara T. Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides. Curr Opin Pharmacol 2004;4:139-46 (Pubitemid 38444048)
66. Isomura I, Morita A. Regulation of NF-kB signaling by decoy oligodeoxynucleotides. Microbiol Immunol 2006;50:559-63 (Pubitemid 44285282)
67. Mcevoy LM, Parham C, Zhang J, Ehrhardt R. NF-kB oligonucleotide decoy molecules. US20070078102; 2007
68. Morishita R, Aoki M, Ogihara T, Kawasaki T. Decoy-containing pharmaceutical compositions and method of using the same. US20070142314; 2007
69. Sawa Y. Agents for protection from neointimal formation in grafts comprising an nfkappab decoy. US20060233815; 2006
70. Nakajima T, Temma A, Suzuki N. Novel Oligonucleotide and NF-kB Decoy Comprising the Same. US20100167390; 2010
71. Strober W, Fuss I, Kitani A, Fichtner-feighl S. Compositions and Methods for the Treatment of Inflammatory Bowel Disease Utilizing NF-KappaB Decoy Polynucleotides. US2009214630; 2009
72. Morishita R, Aoki M, Ogihara T, et al. Medical composition containing nf-kb decoy for treating and preventing respiratory diseases and method of using the same. US20070183983; 2007
73. Morishita R, Ogihara T, Aoki M, Miyake T. Chimeric (Double) Decoy. US20070259826; 2007
74. Penolazzi L, Lambertini E, Borgatti M, et al. Decoy oligodeoxynucleotides targeting NF-kB transcription factors: induction of apoptosis in human primary osteoclasts. Biochem Pharmacol 2003;66:1189-98 (Pubitemid 37130294)
75. Borgatti M, Breda L, Cortesi R, et al. Cationic liposomes as delivery systems for double-stranded PNA-DNA chimeras exhibiting decoy activity against NF-kB transcription factors. Biochem Pharmacol 2002;64:609-16
76. Penolazzi L, Borgatti M, Lambertini E, et al. Peptide nucleic acid-DNA decoy chimeras targeting NF-kB transcription factors: Induction of apoptosis in human primary osteoclasts. Int J Mol Med 2004;14:145-52
77. Cabrini G, Bezzerri V, Mancini I, et al. Targeting transcription factor activity as a strategy to inhibit pro-inflammatory genes involved in cystic fibrosis: decoy oligonucleotides and low-molecular weight compounds. Curr Med Chem 2010;17(35):4392-404
78. Bodas M, Vij N. The NF-kB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential. Discov Med 2010;9:346-56
79. Kieninger E, Regamey N. Targeting inflammation in cystic fibrosis. Respiration 2010;79:189-90
80. Cooper JA Jr, Parks JM, Carcelen R, et al. Attenuation of interleukin-8 production by inhibiting nuclear factor-kappaB translocation using decoy oligonucleotides. Biochem Pharmacol 2000;59:605-13 (Pubitemid 30085441)
81. Gambari R, Borgatti M, Bezzerri V, et al. Decoy oligodeoxyribonucleotides and peptide nucleic acids-DNA chimeras targeting nuclear factor kappa-B: inhibition of IL-8 gene expression in cystic fibrosis cells infected with Pseudomonas aeruginosa. Biochem Pharmacol 2010;80(12):1887-94
82. Yoshizumi T, Ikeda Y, Kaneda Y, Sueishi K. Ex vivo transfer of nuclear factor-kappaB decoy ameliorates hepatic cold ischemia/reperfusion injury. Transplant Proc 2009;41:1504-7
83. Takahashi T, Togo S, Kumamoto T, et al. Transfection of NF-kB decoy oligodeoxynucleotides into macrophages reduces murine fatal liver failure after excessive hepatectomy. J Surg Res 2009;154:179-86
84. Suzuki M, Inoue G, Gemba T, et al. Nuclear factor-kappa B decoy suppresses nerve injury and improves mechanical allodynia and thermal hyperalgesia in a rat lumbar disc herniation model. Eur Spine J 2009;18:1001-7
85. Shimizu H, Nakagami H, Morita S, et al. New treatment of periodontal diseases by using NF-kB decoy oligodeoxynucleotides via prevention of bone resorption and promotion of wound healing. Antioxid Redox Signal 2009;11:2065-75
86. Penolazzi L, Magri E, Lambertini E, et al. "In vivo" local transfection of a cis element decoy mimicking an estrogen receptor alpha gene promoter region induces apoptosis of osteoclasts following application of orthodontic forces to rat teeth. Apoptosis 2006;11:1653-6 (Pubitemid 44253681)
87. Kim KH, Lee ES, Cha SH, et al. Transcriptional regulation of NF-kB by ring type decoy oligodeoxynucleotide in an animal model of nephropathy. Exp Mol Pathol 2009;86:114-20
88. Kimura S, Egashira K, Chen L, et al. Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension 2009;53:877-83
89. De Stefano D, De Rosa G, Maiuri MC, et al. Oligonucleotide decoy to NF-kB slowly released from PLGA microspheres reduces chronic inflammation in rat. Pharmacol Res 2009;60:33-40
90. Li YT, He B, Wang YZ, Wang J. Effects of intratracheal administration of nuclear factor-kappaB decoy oligodeoxynucleotides on long-term cigarette smoke-induced lung inflammation and pathology in mice. Respir Res 2009;10:79
91. Park GY, Christman JW. Nuclear factor kappa B is a promising therapeutic target in inflammatory lung disease. Curr Drug Targets 2006;7:661-8 (Pubitemid 43827261)
92. Fichtner-Feigl S, Young CA, Kitani A, et al. IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology 2008;135(6):2003-13
93. Han W, Liu GN. EGR-1 decoy ODNs inhibit vascular smooth muscle cell proliferation and neointimal hyperplasia of balloon-injured arteries in rat. Life Sci 2010;86(7-8):234-43
94. Morishita R, Gibbons GH, Horiuchi M, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995;92(13):5855-9
95. Gambari R, Penolazzi L, Piva R. Double-Stranded Synthetic Oligonucleotides Useful For Inducing Apoptosis of Osteoclasts For the Treatment of Osteopenic Pathologies. US20080171717; 2008
96. Huang K, Lin J. Transcription Factor Decoys And Use Thereof. US20110054010; 2011
97. Hunt AC, Lim C, Garovoy MR. Polynucleotide decoys that inhibit MHC-II expression and uses thereof. US5859226; 1999
98. Parham C, Mcevoy L, Zhang J, Rao X. E2F oligonucleotide decoy molecules. US20050164240; 2005
99. Mcevoy L, Powell L, Zhang J, Morris K. HIF oligonucleotide decoy molecules. US20050215503; 2005
100. Grandis J, Johnson DE, Leong P. STAT3 decoy oligonucleotides and uses thereof. US20060293264; 2006
101. Klem R. Methods and composition for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof. US7060690; 2006
102. Mauviel A. Blocking Sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis. US20020137715; 2002
103. Walsh K. GATA-6 transcription factor: compositions and methods. US5990092; 1999
104. Arai K, Miyatake S, Takemoto N. Decoy for treating and/or preventing th2 cytokine-associated allergic disease, gata3 mutant protein and medicinal compositions containing the same. US20050222062; 2005
105. Hecker M, Wagner A. Modulation of expression of STAT-1 dependent genes. US7320964; 2008
106. Jones WK. Oligonucleotide decoys and methods of use. US20090099108; 2009
107. Fillmore H, Martin Rege JI. Chimeric transcription factor decoy oligonucleotides. US20080233644; 2008
108. Wang Z. Transcription factor decoy oligodeoxynucleotides having multiple cis elements. US20090227661; 2009
109. Klem RE. Methods and composition for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers and hybrid oligomers thereof. US7060690; 2006
110. Lee I, Morishita R. Circular dumbell oligodeoxynucleotides (CDODN) containing DNA binding sites of transcription. US20070014840; 2007
111. Bou-Gharios G, Garrett LA, Rossert J, et al. A potent far-upstream enhancer in the mouse pro alpha 2(I) collagen gene regulates expression of reporter genes in transgenic mice. J Cell Biol 1996;134(5):1333-44 (Pubitemid 26300176)
112. Shinohara K, Hamamoto H, Kobayashi K, et al. Composition for external application comprising transcription factor decoy as active ingredients. US2011092438; 2011
113. Lee I, Morishita R. Cyclic dumbell decoy oligodeoxynucleotide (CDODN) containing transcribed DNA-bound site. JP2009142295; 2009
114. Morishita R, Aoki M, Ogihara T, Kawasaki T. Decoy-containing pharmaceutical compositions and method of using the same. JP2009102428; 2009
115. Gemba T, Ueno N. Transcription factor decoy. US2009143319; 2009
116. Naparstek Y, Hershko A. Regulatory sequences derived from IL-10 promoter and uses thereof in modulation of immune response. WO2009024986; 2009
117. Mcevoy L, Powell L, Zhang J, Morris K. HIF oligonucleotide decoy molecule. JP2008109935; 2008
118. Hecker M, Rauto M, Wagner A. Regulation of transcription of gene within varscular cell. JP2007135603; 2007
119. Nakajima T, Tsuchimochi K, Yagishita N, et al. Decoy Nucleic Acid to Synoviolin Gene Promoter. US2009029929; 2009
120. Nakajima T, Yamasaki S, Yagishita N, et al. Nerve Cell Differentiation Inducer. US2007219150; 2007
121. Parham C, Mcevoy L, Zhang J, Rao X. E2F oligonucleotide decoy molecules. WO2005035547; 2005
122. Hoel AW, Conte MS. Edifoligide: a transcription factor decoy to modulate smooth muscle cell proliferation in vein bypass. Cardiovasc Drug Rev 2007;25(3):221-34 (Pubitemid 47547466)
123. Mann MJ, Whittemore AD, Donaldson MC, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 1999;354(9189):1493-8 (Pubitemid 29502101)
124. Kaneda Y, Morishita R, Dzau VJ. Prevention of restenosis by gene therapy. Ann N Y Acad Sci 1997;811:299-308
125. Egashira K, Suzuki J, Ito H, et al. Long-term follow up of initial clinical cases with NF-kappaB decoy oligodeoxynucleotide transfection at the site of coronary stenting. J Gene Med 2008;10(7):805-9 (Pubitemid 352003923)
126. Jun-Ichi S, Hiroshi I, Ryo G, et al. Initial clinical cases of the use of a NF-kappaB decoy at the site of coronary stenting for the prevention of restenosis. Circ J 2004;68(3):270-1
127. Conte MS, Bandyk DF, Clowes AW, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 2006;43(4):742-51
128. Alexander JH, Hafley G, Harrington RA, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 2005;294(19):2446-54 (Pubitemid 41627922)
129. Alexander JH, Ferguson TB Jr, Joseph DM; PREVENT IV Investigators. The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics. Am Heart J 2005;150(4):643-9 (Pubitemid 41396491)
130. Cai X, Freedman NJ. New therapeutic possibilities for vein graft disease in the post-edifoligide era. Future Cardiol 2006;2(4):493-501 (Pubitemid 44270119)
131. Nielsen PE, Egholm M, Berg RH, Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 1991;254:1497-500 (Pubitemid 21917487)
132. Uhlmann E. Peptide nucleic acids (PNA) and PNA-DNA chimeras: from high binding affinity towards biological function. Biol Chem 1998;379:1045-52 (Pubitemid 28456816)
133. Romanelli A, Pedone C, Saviano M, et al. Molecular interactions with nuclear factor kappaB (NF-kB) transcription factors of a PNA-DNA chimera mimicking NF-kB binding sites. Eur J Biochem 2001;268:6066-75 (Pubitemid 33132028)
134. Yuan X, Ma Z, Zhou W, et al. Lipid-mediated delivery of peptide nucleic acids to pulmonary endothelium. Biochem Biophys Res Commun 2003;302(1):6-11 (Pubitemid 36268910)
135. Ganguly S, Chaubey B, Tripathi S, et al. Pharmacokinetic analysis of polyamide nucleic-acid-cell penetrating peptide conjugates targeted against HIV-1 transactivation response element. Oligonucleotides 2008;18(3):277-86
136. Upadhyay A, Ponzio NM, Pandey VN. Immunological Response to Peptide Nucleic Acid and its Peptide Conjugate Targeted to Transactivation Response (TAR) Region of HIV-1 RNA Genome. Oligonucleotides 2008;18:329-36
137. MacQuarrie KL, Fong AP, Morse RH, Tapscott SJ. Genome-wide transcription factor binding: beyond direct target regulation. Trends Genet 2011;27(4):141-8
138. Ladunga I. An overview of the computational analyses and discovery of transcription factor binding sites. Methods Mol Biol 2010;674:1-22
139. Collas P. The current state of chromatin immunoprecipitation. Mol Biotechnol 2010;45(1):87-100